Nurse Practitioner Chronicles

  NFECTIOUS DISEASE   |   STI PREVENTION & SEXUAL HEALTH June 2026   |   NP Chronicles Clinical Education   DoxyPEP in 2026: What Every NP Needs to Know About Prescribing, Patient Selection, and Antibiotic Stewardship By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC Based on: Bacic Lima D. DoxyPEP in 2026: Who Benefits, How to Prescribe, and What to Watch. Infectious Disease Special Edition. April 23, 2026. idse.net   CLINICAL BOTTOM LINE DoxyPEP — doxycycline 200 mg taken within 72 hours after unprotected sexual exposure — is now CDC-endorsed, evidence-backed, and increasingly part of routine STI prevention practice for MSM and transgender women who have sex with men. NPs in primary care, sexual health, family practice, telehealth, and urgent care settings are encountering patients who have already heard of it and want to discuss it. This post gives you everything you need: the trial data, candidacy crit...

PHARMACOLOGY UPDATE   |   ANTIMICROBIAL THERAPY June 2026   |   NP Chronicles Clinical Education   Zaynich Is Here: What NPs Need to Know About the FDA's Newest Antibiotic for Complicated UTI By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC   CLINICAL BOTTOM LINE Cefepime-zidebactam (Zaynich) received FDA approval in June 2026 for complicated UTI (cUTI) and acute pyelonephritis (AP) caused by susceptible gram-negative pathogens, including drug-resistant strains. In the pivotal Phase 3 trial, it outperformed meropenem at the primary endpoint (89% vs. 68.4%) — a clinically meaningful difference that NPs treating hospitalized patients with resistant infections need to know.   Why This Approval Matters Antimicrobial resistance is one of the defining clinical challenges of our era. For NPs working in hospital-based, telehealth urgent care, or primary care settings, complicated urinary tract infections — espe...